• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·249420.KS
Share

Ildong Pharmaceutical Co., Ltd. Stocks

₩ 14990Last Updated 07.08.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₩ 298.50M

₩ 14990
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Poor growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes various medications such as anti-diarrheal agents, antibiotics, antifungals, antivirals, antihistamines, anticancer drugs, NSAIDs, and pain relievers, along with essential vitamins, minerals, and nutritional supplements. The company also produces treatments for numerous bodily systems, including cardiovascular, central nervous, dental, endocrine, gastrointestinal, respiratory, topical, and urogenital health, as well as those for blood circulation. Beyond pharmaceuticals, Ildong offers raw material drugs, health foods, cosmetics, and specialized medical devices, such as scar treatment products. Their range also extends to unique treatments for conditions like osteoarthritis, wound care, artificial tears, and feminine hygiene products. In addition to its product offerings, the company manages licenses and provides contract manufacturing services. With a global reach, Ildong Pharmaceutical exports its products to approximately 20 countries. Furthermore, the company has entered into a strategic collaboration with Evotec SE, leveraging Evotec's INDiGO platform to accelerate the development of its proprietary projects.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, undervalued o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 19:49

Berkshire Hathaway has reduced its "cash cushion" for the first time in four years

08.08.2026 16:01

Small-Cap Highlights: SolarEdge Forecast, Bitdeer's $4.7 Billion Deal, Replimune's Success

08.08.2026 13:01

A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026